Gregory T. Carter
University of Washington
196 Papers
845 Citations
Gregory T. Carter is an academic researcher from University of Washington. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 41, co-authored 140 publications. Previous affiliations of Gregory T. Carter include University of California, Berkeley & University of Washington Medical Center.
Chat about Author
Papers
Profiles of neuromuscular diseases. Duchenne muscular dystrophy.
Craig M. McDonald,Richard T. Abresch,Gregory T. Carter,William M. Fowler,E. R. Johnson,David D. Kilmer,B. J. Sigford +6 more
TL;DR: A tremendous heterogeneity of severity among males with Becker's muscular dystrophy is suggested, with mean intellectual and neuropsychologic function within normal limits, but with a large variability in intelligence quotient scores.
1.1K
Clinical features of late-onset Pompe disease: a prospective cohort study.
John H. J. Wokke,Diana M. Escolar,Alan Pestronk,Kenneth M. Jaffe,Gregory T. Carter,Leonard H. van den Berg,Julaine Florence,J. Mayhew,Alison Skrinar,Deyanira Corzo,Pascal Laforêt +10 more
TL;DR: Symptom duration was identified as the best predictor of the extent of skeletal and respiratory muscle weakness and outcome measures were demonstrated to be safe and reliable.
164
Medicinal Cannabis: A Survey Among Health Care Providers in Washington State
TL;DR: Clinicians who had issued MC authorizations were more likely to have received MC training than those who had not issued MC authorization, and providers who had and had not authorized MC for patients had low knowledge and comfort level related to recommending MC.
154
Side Effects of Commonly Prescribed Analgesic Medications
Gregory T. Carter,Vicky Duong,Stanley Ho,Kathryn C. Ngo,Christopher L. Greer,Douglas L. Weeks +5 more
TL;DR: Analgesics, including opioids, steroidal and nonsteroidal anti-inflammatory drugs, aspirin, acetaminophen, antiepileptics, and serotonin-norepinephrine reuptake inhibitors, are medications commonly used to treat many forms of pain but all of these agents may have significant adverse side effects.
134
Profiles of neuromuscular diseases. Spinal muscular atrophy.
Gregory T. Carter,Richard T. Abresch,William M. Fowler,E. R. Johnson,David D. Kilmer,Craig M. McDonald +5 more
TL;DR: Timed motor performance and functional evaluations indicated that muscle weakness translated to substantial disability in both SMA II and III, with more severe impairment noted in SMA I.
114